Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following…
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing…
Unique treatment program offers promising results for Long COVID patients who are experiencing extreme symptoms related to the virus.FAYETTEVILLE, AR…
Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial…
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data…
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with…
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…
SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…